Royal Bank of Canada
STRO icon

Royal Bank of Canada’s Sutro Biopharma STRO Stock Holding History

Royal Bank of Canada’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
12
+1
+9% +$18 ﹤0.01% 7662
2025
Q4 		$0 Sell
11
-25,888
-100% -$246K ﹤0.01% 7617
2025
Q3 		$225K Buy
25,899
+3,716
+17% +$31.6K ﹤0.01% 5022
2025
Q2 		$159K Buy
22,183
+21,563
+3,478% +$176K ﹤0.01% 5312
2025
Q1 		$4K Sell
620
-592
-49% -$9.32K ﹤0.01% 6431
2024
Q4 		$22K Buy
1,212
+384
+46% +$11.7K ﹤0.01% 6075
2024
Q3 		$28K Buy
828
+58
+8% +$2.27K ﹤0.01% 5982
2024
Q2 		$23K Buy
770
+628
+442% +$24.8K ﹤0.01% 6017
2024
Q1 		$8K Sell
142
-1,741
-92% -$76.9K ﹤0.01% 6293
2023
Q4 		$81K Buy
1,883
+871
+86% +$27.6K ﹤0.01% 5743
2023
Q3 		$35K Buy
1,012
+384
+61% +$16.7K ﹤0.01% 5968
2023
Q2 		$29K Buy
628
+229
+57% +$11.4K ﹤0.01% 6029
2023
Q1 		$18K Sell
399
-346
-46% -$22K ﹤0.01% 6071
2022
Q4 		$60K Buy
745
+685
+1,142% +$47.6K ﹤0.01% 5774
2022
Q3 		$3K Buy
60
+35
+140% +$2.07K ﹤0.01% 6923
2022
Q2 		$1K Sell
25
-288
-92% -$16.1K ﹤0.01% 7202
2022
Q1 		$26K Sell
313
-579
-65% -$55.1K ﹤0.01% 6470
2021
Q4 		$132K Buy
892
+759
+571% +$136K ﹤0.01% 5726
2021
Q3 		$25K Buy
133
+90
+209% +$17.1K ﹤0.01% 6583
2021
Q2 		$8K Sell
43
-229
-84% -$44.8K ﹤0.01% 6951
2021
Q1 		$62K Buy
272
+224
+467% +$53.2K ﹤0.01% 5761
2020
Q4 		$10K Buy
+48
New +$7.95K ﹤0.01% 6387
2020
Q3 		– Sell
-2
Closed – – 6917
2020
Q2 		$0 Sell
2
-114
-98% -$10.9K ﹤0.01% 6892
2020
Q1 		$12K Buy
116
+17
+17% +$1.79K ﹤0.01% 5769
2019
Q4 		$11K Buy
+99
New +$10.2K ﹤0.01% 6112

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Royal Bank of Canada's STRO Position: Q1 2026 in Review

Royal Bank of Canada increased its Sutro Biopharma (STRO) stake by 9.1% in Q1 2026, buying an estimated $18 and bringing the position to 12 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7662.

Royal Bank of Canada first reported a position in STRO in Q4 2019 and has held it in 25 quarters since. The position peaked at $225K in Q3 2025. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Royal Bank of Canada held 12 shares of Sutro Biopharma worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 1 Sutro Biopharma share in Q1 2026, an estimated $18.
  • Sutro Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7662 holding.
  • Royal Bank of Canada first reported a position in Sutro Biopharma in Q4 2019 and has held it in 25 quarters since.
  • Royal Bank of Canada's Sutro Biopharma position peaked at $225K in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.